The startup offers a digital health platform that analyzes eye movements as a biomarker to evaluate brain health in patients with neurological disorders. This technology provides objective assessments that can enhance early diagnosis and monitoring of conditions such as Alzheimer's and Parkinson's disease.
Funding
$3.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NINSPASHUCFounders
Product
Problem
Diagnosing and monitoring neurological disorders such as Alzheimer's and Parkinson's disease often rely on subjective assessments and late-stage symptom detection. Current diagnostic methods lack objective, easily accessible biomarkers for early and accurate evaluation of brain health.
Solution
The company provides a digital health platform that uses eye-tracking technology as a biomarker to objectively assess brain health. Their platform analyzes subtle eye movement patterns, which are correlated with neurological function, to aid in the early diagnosis and monitoring of neurological disorders. By providing quantitative data on eye movements, the platform offers clinicians insights into cognitive and motor functions, enabling more informed treatment decisions and personalized care plans. The technology aims to improve the accuracy and efficiency of neurological assessments, leading to earlier interventions and better patient outcomes.
Target Audience
The primary target audience includes neurologists, geriatricians, and other healthcare professionals involved in the diagnosis and management of neurological disorders, as well as clinical researchers studying brain health.
Features
- Eye-tracking based assessment of neurological function
- Objective biomarkers for early detection of neurological disorders
- Quantitative data on eye movement patterns correlated with cognitive and motor functions
- Cloud-based platform for data storage and analysis
- Secure data transmission and HIPAA compliance